Cell, tissue and gene therapies offer significant potential to treat diseases with high unmet medical needs, and consist of human cell and tissue products for medical use and advanced therapy medicinal products (ATMPs). IFPMA shares points to consider when promoting regulatory convergence and reliance approaches for ATMPs.
Read more
As the global architecture for pandemic preparedness and response is discussed, IFPMA shares practical solutions and recommends focusing on five priorities.
Read more
As the global architecture for pandemic preparedness and response is discussed, IFPMA shares practical solutions and recommends focussing on five priorities.
Read more
On 6 February 2023, IFPMA delivered a statement for the WHO EB152 agenda item related to the Pandemic Influenza Preparedness Framework.
Read moreOn 2 February 2023, IFPMA delivered a statement for the agenda item related to the prevention and control of non-communicable diseases and mental health at the WHO EB152.
Read moreOn 1 February 2023, IFPMA delivered a statement for the agenda item related to universal health coverage at the 152 Session of the World Health Organization Executive Board.
Read moreOn 1 February 2023, IPSF submitted a statement delivered on behalf of IPSF, IAPO, and IFPMA for the WHO EB152 agenda item related to substandard and falsified medical products.
Read moreIFPMA delivered a constituency statement for the agenda item related to strengthening the global architecture for health emergency preparedness, response, and resilience at the 152nd session of the Executive Board at the World Health Organization in Geneva.
Read moreFollowing on the heels of COVID-19, global rules on pandemic preparedness and response are being overhauled. Negotiations on a Global Pandemic Accord will kick off in February 2023, and the International Health Regulations (IHR) on responding to global public health emergencies are being revised. Against that background, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) requested that...
Read more
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the body representing the research-based pharmaceutical industry to the United Nations and the global stage, announced that Elliot Dunster will be joining the trade body on 17 April as Executive Director of Communications. He will be taking over the role from Abigail Jones, who is retiring in the course of 2023.
Read more
IFPMA encourages the consistent coordination of the INB and IHR processes to ensure a non-duplicative, fit-for-purpose outcome for all.
Read moreChildhood vaccination is recognized as one of the greatest medical success stories of the 20th century. Apart from clean water, no other intervention has had a bigger impact on global public health, especially for children, their families, and communities. In fact, vaccines have done such a good job of eradicating, eliminating or controlling certain infectious diseases that many of us have forgotten, or no longer worry, that our children or loved ones might still contract diseases like polio, measles or diphtheria.
Read more